基础医学与临床 ›› 2013, Vol. 33 ›› Issue (9): 1205-1208.

• 研究论文 • 上一篇    下一篇

英夫力西和环孢素治疗难治性炎症性肠病的近期疗效比较

杨欣艳,范如英,刘云云,盛剑秋,李世荣   

  1. 北京军区总医院
  • 收稿日期:2013-07-04 修回日期:2013-07-09 出版日期:2013-09-05 发布日期:2013-08-28
  • 通讯作者: 李世荣 E-mail:li.shirong@yahoo.cn

Short-term effects of Infliximab and Cyclosporin as rescue therapy for patients with refractory-IBD

  • Received:2013-07-04 Revised:2013-07-09 Online:2013-09-05 Published:2013-08-28

摘要: 目的 评估英夫力西(IFX)和环孢素(CsA)挽救性治疗难治性炎症性肠病(inflammatory bowl disease, IBD)患者的治疗效果。方法 前瞻性、非随机收集18例难治性炎症性肠病患者进入观察。12例UC患者中,6例应用英夫力西(IFX);6例应用(CsA)。6例CD患者全部用IFX治疗。对比14周和30周的疗效。结果 14周随访时,6例IFX治疗和6例CsA治疗的UC患者中,各有5例有效;1例无效。30周时,6例IFX组中,3例有效,1例无效;6例CsA组中,4例有效,1例无效。14周随访时,6例CD患者中,3例有效,1例无效。30周时,6例CD患者中,4例有效,没有无效病例。IFX组出现2例皮疹,CsA组1例皮疹,4例手抖。CsA价格较便宜。结论IFX和CsA挽救性治疗难治性炎症性肠病的疗效相同,建议经济条件较好的患者选用前者,经济承受能力较差者可选用后者。

关键词: 英夫利西, 环孢素, 难治性炎症性肠病, 近期疗效

Abstract: Objectives To evaluate the effect of Infliximab(IFX) and cyclosporin(CsA) as rescue therapy for patients with refractory-IBD. Methods Prospectively and not randomly, 18 cases with refractory-IBD were invited to participate in the study. Of 12 patients with UC, 6 cases received IFX; 6 patients took CsA. All of 6 patients with CD were given IFX. Comparing the effect of IFX with CsA at 12 weeks and 30 weeks. Results 5 UC cases responded to IFX and CsA, 1 case failed to therapy respectively for both groups at 14 weeks. Of 6 UC cases with IFX 3 were effects and 1 failed , but 4 cases responded and 1 case failed for CsA group at 30 weeks. Of 6 CD cases, 3 responded to IFX while 1 case failed at 14 weeks. Of 6 CD cases treated with IFX, 4 patients improved, no invalid case was found at 30 weeks. Rash occurred in 2 cases treated with IFX, while among cases treated with CsA, 1 developed tatter and 4 had hands tremor. Conclusions As rescue therapy for patients with refractory IBD, IFX and CsA presented the same effectiveness, Patients with good economic conditions had better take the fomer, those with relatively poor economic bear ability might as well choose the latter.

Key words: Infliximab, Cyclosporin, refractory IBD, short-term effect